Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-024-02195-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Naotaka Kugiyama und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, Kumamoto, 860-0811,…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Biomarkers, Tumor, Antigens, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, JSPS KAKENHI.
Abstract (Originalsprache)
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Mac2-binding protein glycosylated isomer (M2BPGi), a known biomarker for liver fibrosis, is also elevated in other fibrotic tissues. However, its role in PDAC remains unexplored. This study investigates the potential of M2BPGi as a prognostic biomarker for PDAC and elucidates its role in cancer progression. METHODS: We analyzed serum M2BPGi levels in 83 PDAC patients and 60 healthy controls, examining the relationship with clinical outcomes. Tissue immunostaining and in vitro experiments were conducted to investigate M2BPGi-secreting cells and its role. RESULTS: Serum M2BPGi levels were significantly higher in PDAC patients than in controls (0.98 vs. 0.59, p < 0.0001). Notably, elevated serum M2BPGi was associated with worse progression-free survival (144 days vs. 260 days, p = 0.017) and overall survival (OS) (245 days vs. 541 days, p < 0.001) following chemotherapy. Multivariable Cox regression analysis further confirmed that a high serum M2BPGi level is an independent risk factor for OS (HR: 2.44, 95% CI 1.26-4.74, p = 0.008). Immunostaining revealed that M2BPGi is secreted by both cancer cells and cancer-associated fibroblasts (CAFs), with high M2BP expression in CAFs correlating with poor prognosis. Furthermore, M2BPGi-secreting CAFs exhibited characteristics of inflammatory CAFs. M2BPGi directly activated mTOR signaling and epithelial-mesenchymal transition in PDAC cells, enhancing their invasive and migratory capabilities. CONCLUSIONS: Our findings identify M2BPGi as a promising prognostic biomarker for PDAC. Moreover, we demonstrate that inflammatory CAFs promote tumor invasion and contribute to poor outcomes by secreting M2BPGi, revealing a novel mechanism of PDAC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, Kumamoto, 860-0811, Japan.
- Department of Cell Pathology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Kumamoto City Hospital, Kumamoto, Japan.
- Department of Gastroenterological Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Yasuhito Tanaka
Förderung
- Japan Agency for Medical Research and Development
- JSPS KAKENHI
Zitieren
APA
Kugiyama, N., Nagaoka, K., Yamada, R., Watanabe, T., Yamazaki, H., Ushijima, S., Otsuka, F., Uramoto, Y., Iwasaki, H., Yoshinari, M., Hashigo, S., Hayashi, H., Ishimoto, T., Komohara, Y., & Tanaka, Y. (2025). Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02195-8
Vancouver
Kugiyama N, Nagaoka K, Yamada R, Watanabe T, Yamazaki H, Ushijima S, et al. Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02195-8
BibTeX
@article{Kugiyama2025,
author = {Kugiyama, Naotaka and Nagaoka, Katsuya and Yamada, Rin and Watanabe, Takehisa and Yamazaki, Hajime and Ushijima, Shinya and Otsuka, Fumiya and Uramoto, Yukiko and Iwasaki, Hajime and Yoshinari, Motohiro and Hashigo, Shunpei and Hayashi, Hiromitsu and Ishimoto, Takatsugu and Komohara, Yoshihiro and Tanaka, Yasuhito},
title = {Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-024-02195-8}
}
EUVIMED